Then, we characterized the ability of these recombinant FN fragments to agonize TLR4, activate DCs, stimulate CD8+ T cell expansion, and induce functional CTLs, where functionality was judged by cytotoxicity in a tumor vaccine model. The gene discussed is FN1; the disease is neoplasm.